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Abstract
Purpose A combined chemotherapy of taxane and plati-
num, with or without anthracycline, has been used as a
standard ﬁrst-line regimen. The purpose of this study was
to investigate the effectiveness of second-line chemother-
apy for treatment of advanced or recurrent endometrial
carcinoma previously treated with a combined chemo-
therapy of taxane and platinum, with or without
anthracycline.
Methods During the 2000–2008 study period, 723
patients were diagnosed with endometrial cancer at the
Departments of Obstetrics and Gynecology of the Osaka
University and the Osaka Rosai Hospitals, Osaka, Japan.
The subset of these cases that eventually required treatment
by second-line chemotherapy was retrospectively analyzed.
Results Response rate to second-line chemotherapy was
25%. Treatment-free interval (TFI) of C or\6 months was
demonstrated to be signiﬁcantly associated with the
response to second-line chemotherapy (P = 0.0026),
progression-free survival (P = 0.0003) and overall sur-
vival (P = 0.025). The second-line chemotherapy similar
to the ﬁrst-line regimen was ineffective in all the 7 cases
(100%) whose TFI was shorter than 6 months. Multivariate
analysis showed that TFI was the most signiﬁcantly
important factor predicting the effectiveness of second-line
chemotherapy (the adjusted hazard ratio of TFI on PFS and
OS: 3.482, 95% CI, 1.641–7.388, P = 0.0012, and 2.341,
95% CI, 1.034–5.301, P = 0.042, respectively).
Conclusions Our present study provides, for the ﬁrst
time, evidence that the majority of refractory or recurrent
diseases, if they occur within 6 months of a ﬁrst-line che-
motherapy using taxane and platinum with or without
anthracycline, are non-responsive to the current regimens
of second-line chemotherapy.
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MPA MedroxyProgesterone Acetate
Y. Ueda  T. Egawa-Takata  T. Miyatake  S. Matsuzaki 
T. Yokoyama  K. Yoshino  M. Fujita  T. Enomoto (&) 
T. Kimura
Department of Obstetrics and Gynecology,
Osaka University Graduate School of Medicine,
2-2, Yamadaoka, Suita, Osaka 565-0871, Japan
e-mail: enomoto@gyne.med.osaka-u.ac.jp
Y. Ueda
e-mail: ZVF03563@nifty.ne.jp
T. Miyake
Department of Obstetrics and Gynecology,
Osaka Rosai Hospital, 1179-3, Nagasone,
Sakai, Kita-ku, Osaka 591-8025, Japan
123
Cancer Chemother Pharmacol (2011) 67:829–835
DOI 10.1007/s00280-010-1384-zTAP or AP Anthracycline (doxorubicin)
plus Platinum (cisplatin) (with, or
without, the Taxane, paclitaxel)
TEC or TC Taxane paclitaxel and Carboplatin
(with, or without, the anthracycline,
Epirubicin)
TEP Taxane (paclitaxel), Epirubicin and
the Platinum, cisplatin
TCw, TCm, TECm TC or TEC administered
on a weekly or monthly regimen
Introduction
The incidence of endometrial carcinoma, already the most
common malignancy of the female pelvis and the fourth
most common cancer among women in the United States,
has been increasing steadily during the last three decades
[1]. In approximately 75% of patients, the tumor is still
conﬁned to the uterus at diagnosis (FIGO stage I), and thus,
there is a good prognosis [2]. However, the prognosis for
advanced endometrial carcinomas, with extra-pelvic met-
astatic dissemination, is extremely poor, and the 5-year
survival rate is a mere 5–32% [1]. Irradiation was usually
performed as post-operative adjuvant therapy for early
cases considered being at risk of recurrence and for most
advanced cases [3]. Recently, systemic adjuvant chemo-
therapy, compared to adjuvant irradiation, was reported to
signiﬁcantly improve the prognosis of these cases [4, 5].
About one-fourth of those patients, treated for what was
thought to be an early-stage endometrial cancer, go onto
develop a recurrence. Unfortunately, 3–19 years after
treatment for the recurrence, only 7.7% of the patients were
alive and without evidence of disease [3]. Recurrences,
restricted to the vaginal vault, are relatively better treated
with radiotherapy. However, in most cases of relapse, the
disease had spread to other sites, including pelvic and para-
aortic lymph nodes, the peritoneum of the pelvis and
abdominal cavity, and the lungs. For these cases, systemic
chemotherapy is usually required.
Cisplatin and doxorubicin were shown to be the most
effective drugs for both advanced and recurrent endome-
trial carcinomas; paclitaxel was also reported to be useful
[6, 7]. A Gynecologic Oncology Group’s (GOG) study
showed that a tripartite regimen of the Taxane paclitaxel,
plus the Anthracycline doxorubicin and the Platinum drug
cisplatin (TAP), provided a better response, as measured by
progression-free and overall survival rates, than without the
taxane (AP). However, there were signiﬁcant adverse side
effects in the TAP group [8]. A modiﬁed TAP regimen,
with the Taxane paclitaxel and Epirubicin (a semi-synthetic
stereoisomer of doxorubicin) plus the Platinum drug
cisplatin (TEP), was a more effective combination che-
motherapy, with a 73% response rate for advanced endo-
metrial carcinomas, suggesting a possible future role of
TEP therapy as the ﬁrst-line treatment for advanced
endometrial carcinomas [9]. A combination chemotherapy
of the Taxane paclitaxel and Carboplatin (TC), which is a
standard regimen for ovarian carcinoma, was also shown to
be a well-tolerated, active adjuvant therapy regimen for
advanced endometrial carcinomas [10]. More recently, a
combination chemotherapy of the Taxane paclitaxel, Epi-
rubicin and Carboplatin (TEC) was demonstrated to be
active and tolerable in patients with advanced metastatic
and recurrent endometrial carcinomas [11].
Based on these ﬁndings, a combined chemotherapy of
taxane and platinum, with or without anthracycline, has
been used as a standard ﬁrst-line regimen for both unre-
sected and recurrent endometrial carcinomas and also as an
adjuvant therapy for resected cases with a high risk of
recurrence. However, a second-line regimen for the treat-
ment of advanced or recurrent endometrial carcinoma
previously treated with a combined chemotherapy of tax-
ane and platinum, with or without anthracycline, has yet to
be established. We hoped our ﬁndings would change that.
In our current study, the effectiveness of second-line che-
motherapy and the various clinical factors that associate
with the prognosis of advanced or recurrent endometrial
carcinoma previously treated with a combination chemo-
therapy of taxane and platinum, with or without anthra-
cycline, were retrospectively investigated.
Materials and methods
Materials
Patients’ characteristics
During the 9-year study period of 2000–2008, we diag-
nosed 723 endometrial carcinomas in Japanese women at
the Departments of Obstetrics and Gynecology of the
Osaka University and the Osaka Rosai Hospitals, Osaka,
Japan. Traditionally, our department has used either a
monthly delivered combination of Taxane (paclitaxel) and
Carboplatin (with, or without, the anthracycline Epirubicin,
TEC or TC, respectively) or a weekly administered TC
regimen as the ﬁrst-line adjuvant therapy for resected
endometrial carcinomas and also as the ﬁrst-line salvage
therapy for unresected and recurrent diseases. Patients were
enrolled in the present study, after obtaining their written
informed consent, if they were treated by a second-line
chemotherapy for their recurrent disease, after ﬁrst having
an initial ﬁrst-line adjuvant or salvage TEC or TC therapy.
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123In the initial ﬁrst-line monthly TEC (TECm) treatment,
paclitaxel (150 mg/m
2), carboplatin (AUC = 4) and epi-
rubicin (50 mg/m
2) were administered intravenously every
3–4 weeks. The dose of chemotherapy drugs appropriate
for our Japanese population was determined in phase I/II
studies we had previously conducted (to be described in
detail elsewhere). In the monthly TC (TCm) therapy,
paclitaxel (175 mg/m
2) and carboplatin (AUC = 5) were
also administered intravenously every 3–4 weeks, based on
previous reports [12, 13]. In the weekly TC regimen
(TCw), paclitaxel (80 mg/m
2) and carboplatin (AUC = 2)
were administered intravenously on days 1, 8 and 15 on a
4-week cycle [14, 15].
The clinicopathological features of these cases, includ-
ing the age of the patient, the histology and initial stage of
the disease and the regimen of the ﬁrst and second-line
chemotherapies, were retrospectively reviewed utilizing
their clinical records, including physical examination
notes, radiological reports, operative records and histopa-
thology reports. The histological diagnoses were made by
authorized pathologists from the Department of Pathology
of the Osaka University and the Osaka Rosai Hospitals.
Methods
In order to evaluate the therapeutic effect of second-line
chemotherapy, previously described standard criteria from
the World Health Organization [16] and others (Pectasides
et al. [17–19] were used. The tumors were assessed with a
CT scan and/or MRI at baseline and every three treatment
courses thereafter. A complete response (CR) was deﬁned
as the disappearance of all known disease, determined by
two observations not less than 4 weeks apart. Partial
response (PR) was deﬁned as a 50% or more reduction in
the summed products of the two largest perpendicular
dimensions of bi-dimensionally measurable lesions, for at
least 4 weeks. Stable disease (SD) was deﬁned as a less
than 50% decrease, or a less than 25% increase, of tumor
size, with no new detectable lesions. Progressive disease
(PD) was deﬁned as a greater than 25% increase in tumor
size or as the appearance of new lesions.
Progression-free survival (PFS) was measured from
the date of the last administration of chemotherapy to the
date of the radiological or pathological relapse or to the
date of the last follow-up. Overall survival (OS) was
deﬁned as the period from the start of chemotherapy to
the patient’s disease-speciﬁc death or to the date of the
last follow-up, as previously described [10]. Treatment-
free interval (TFI) was deﬁned as the period between the
last administration of ﬁrst-line chemotherapy and the
initiation of the second-line chemotherapy, as previously
described [20].
Second-line chemotherapy
Some patients received TECm or TCw (as described above)
as second-line chemotherapy. Others were given docetaxel
(30 mg/m
2) and CPT-11 (60 mg/m
2) (docetaxel ? CPT) on
days 1 and 8, on a 3–4-week cycles, or daily oral medroxy-
progesterone acetate (MPA) (400–600 mg/day). The dose
and schedule of administration of docetaxel ? CPT
appropriateforourJapanesepopulationwasalsodetermined
in our previous phase I/II study (to be described in detail
elsewhere).
Statistical analysis of effect of second-line chemotherapy
The association between sensitivity to second-line che-
motherapy and sensitivity to a TFI was analyzed by
Fisher’s exact test. PFS curves determined by a TFI were
constructed using the Kaplan–Meier method and were
evaluated for statistical signiﬁcance by the log-rank test.
The multivariate Cox proportional hazards model was used
to calculate the signiﬁcant factors contributing to PFS after
second-line chemotherapy. Results were considered to be
signiﬁcant when the P value was\0.05.
Results
Clinical characteristics of the study cases
During the 9-year study period, 40 patients required a
second-line chemotherapy treatment against a recalcitrant
or recurrent disease, after having ﬁrst received an adjuvant
or salvage ﬁrst-line chemotherapy using TECm, TCm or
TCw. The clinicopathological characteristics of these 40
patients are shown in Table 1. Eighty percent (32 out of 40
cases) of the patients received ﬁrst-line TECm therapy; the
other eight cases underwent either monthly or weekly TC
(TCm or TCw) therapy, prior to the second-line chemo-
therapy. No cases were canceled due to second-line che-
motherapy toxicity.
Outcome of the patients after second-line chemotherapy
Among the 40 patients, 24 patients received second-line
TECm, TCm or TCw, 3 received docetaxel ? CPT, 7
received oral MPA therapy, and 6 received oral Etoposide
therapy (Table 2). The overall response rate for second-line
chemotherapy was 25% (0–38%). The PFS was 3.5 months
(0–20 months), and the OS was 10 months (2–44 months).
The response rate, PFS, and OS were not signiﬁcantly
different among the TECm/TCm/TCw, docetaxel ? CPT,
MPA and Etoposide groups.
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chemotherapy
The effect of a TFI, after ﬁrst-line chemotherapy using
TC/TEC, on the tumor’s sensitivity to second-line che-
motherapy was evaluated. Among the 24 patients whose
TFI was equal to or longer than 6 months, CR or PR was
achieved in 10 patients (42%). However, all 16 cases
(100%) whose TFI was shorter than 6 months exhibited
either SD or PD against the second-line chemotherapy.
This association between TFI and sensitivity to a second-
line chemotherapy was statistically signiﬁcant (P = 0.0026
by Fisher’s exact test). These results are tabulated in
Table 3.
Association between TFI and sensitivity to second-line
chemotherapy using taxane and platinum, with or without
anthracycline, was, next, analyzed. Among the 17 patients
whose TFI was equal to or longer than 6 months, CR or PR
was achieved in 9 patients (53%). However, all 7 cases
(100%) whose TFI was shorter than 6 months exhibited
either SD or PD against the second-line chemotherapy.
This association between TFI and sensitivity to a second-
line chemotherapy was statistically signiﬁcant (P = 0.015
by Fisher’s exact test). These results are tabulated in
Table 4.
PFS and OS after second-line chemotherapy by TFI
The differences by TFI in the effectiveness of second-line
chemotherapy regimens were investigated. The median
PFS was 7 months (1–20 months) for the 26 patients
whose TFI was equal to or longer than 6 months, which
Table 1 Clinical characteristics of the study cases
Characteristics Patients (n = 40)
Number %
Age (years)
\60 18 45
C60 22 55
Histology
Endometrioid 32 80
Serous 4 10
Clear cell 1 3
Others 3 8
Initial stage
I1 0 2 5
II 6 15
III 19 48
IV 5 13
First-line chemotherapy
TEC 32 80
TC 7 18
Weekly TC 1 3
All patients received ﬁrst-line chemotherapy using taxane and car-
boplatin (with or without epirubicin, TC/TEC)
TECm monthly administration of taxane (paclitaxel), epirubicin and
carboplatin, TCm monthly administration of paclitaxel and carbo-
platin, TCw weekly administration of paclitaxel and carboplatin
Table 2 Outcome of the patients after second-line chemotherapy
Cases Response rate PFS OS
(%) (months) (months)
TEC/weekly TC 24 38 5.5 (2–20) 13 (3–44)
Docetaxel ? CPT-11 3 33 4 (0–5) 6 (4–10)
MPA (oral) 7 0 1 (0–3) 5 (2–22)
Etoposide (oral) 6 0 2 (1–8) 9 (4–11)
Total 40 25 3.5 (0–15) 10 (2–44)
No signiﬁcant difference was demonstrated among the four groups
(TECm/TCm/TCw, docetaxel ? CPT, MPA and Etoposide)
TECm monthly administration of paclitaxel, epirubicin and carbo-
platin, TCw weekly administration of paclitaxel and carboplatin, TCm
monthly administration of paclitaxel and carboplatin, MPA oral daily
medroxyprogesterone acetate, Etoposide oral daily Etoposide, PFS
progression-free survival, OS overall survival
Table 3 Association between TFI and effectiveness of second-line
chemotherapy
CR/PR SD/PD
TFI C 6 months 10 (42%)
a 14 (58%)
TFI\6 months 0 (0%) 16 (100%)
a
Forty-two percent (10 out of 24 cases) of the patients whose TFI was
equal to or longer than 6 months exhibited sensitivity to second-line
chemotherapy; however, all cases whose TFI was shorter than
6 months were resistant to second-line chemotherapy. This associa-
tion was statistically signiﬁcant (P = 0.0026 by Fisher’s exact test)
TFI treatment-free interval, CR complete response, PR partial
response, SD stable disease, PD progressive disease
a P = 0.0026
Table 4 Association between TFI and sensitivity to second-line
chemotherapy using taxane and platinum, with or without
anthracycline
CR/PR SD/PD
TFI C 6 months 9 (53%)
a 8 (47%)
TFI\6 months 0 (0%) 7 (100%)
a
Fifty-three percent (9 out of 17 cases) of the patients whose TFI was
equal to or longer than 6 months exhibited sensitivity to second-line
chemotherapy; however, all cases whose TFI was shorter than
6 months were resistant to second-line chemotherapy. This associa-
tion was statistically signiﬁcant (P = 0.015 by Fisher’s exact test)
TFI treatment-free interval, CR complete response, PR partial
response, SD stable disease, PD progressive disease
a P = 0.015
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123was signiﬁcantly longer than the 2 months (0–9 months)
for the 14 whose TFI was shorter than 6 months
(P = 0.0003 by log-rank test) (Fig. 1). The median OS was
13 months (3–22 months) for the 26 patients whose TFI
was equal to or longer than 6 months, which was signiﬁ-
cantly longer than the 5.5 months (2–44 months) for the
14 whose TFI was shorter than 6 months (P = 0.025 by
log-rank test) (Fig. 1).
Multivariate Cox proportional hazards analysis
for effectiveness of second-line chemotherapy on PFS
and OS
In order to further support our ﬁnding that a TFI was sig-
niﬁcantly associated with the effectiveness of second-line
chemotherapy, the multivariate Cox proportional hazards
model was utilized. The results are listed in Table 4. The
adjusted hazard ratio (HR) of TFI (C6 months versus
\6 months) on PFS was 3.482 (95% CI, 1.641–7.388) and
that of TFI on OS was 2.341 (95% CI, 1.034–5.301). TFI
was demonstrated to be a signiﬁcant factor in predicting for
PFS and OS (P = 0.0012 and P = 0.042, respectively,
based on the multivariate Cox proportional hazards model)
(Tables 5 and 6).
Conclusions
Endometrial adenocarcinoma is increasingly the most
common malignancy of the female pelvis in the United
States [1]. Although early-stage endometrial carcinomas
have a good prognosis [2], the prognoses for advanced or
recurrent cases are extremely poor (except for recurrences
limited to the vaginal vault, which can generally be treated
successfully with surgery and radiation therapy) [3].
Although a truly successful treatment for advanced or
recurrent endometrial carcinomas has yet to be established,
taxane and platinum (with or without anthracycline, TC/
TEC) have demonstrated at least a partial efﬁcacy [6–11].
Recently, based on these ﬁndings, the combined che-
motherapy of TC/TEC has been used as a standard ﬁrst-line
regimen for unresected and recurrent endometrial carci-
nomas as well as an adjuvant therapy for resected cases
with a high risk of recurrence. However, an effective sec-
ond-line regimen for advanced or recurrent endometrial
carcinomas previously treated with TC/TEC has not yet
been established.
In our present study, we analyzed the outcomes of
patients who, after having received a ﬁrst-line TC or TEC
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Fig. 1 PFS and OS after second-line chemotherapy by TFI. Progres-
sion-free probability and overall probability after second-line che-
motherapy of the patients whose TFI was equal to or longer than
6 months were signiﬁcantly longer than those whose TFI was shorter
than 6 months (P = 0.0003 and P = 0.025, respectively, by the
log-rank test)
Table 5 Multivariate Cox proportional hazards analysis for effec-
tiveness of second-line chemotherapy on PFS
Variable Adjusted HR 95% CI P value
Age (years) 0.14
\60 1
C60 0.573 0.274–1.197
Histology 0.53
Endometrioid 1
Non-endometrioid 1.331 0.546–3.247
Initial stage 0.82
I/II 1
III/IV 1.092 0.517–2.308
TFI 0.0012
C6 months 1
\6 months 3.482 1.641–7.388
The adjusted HR of TFI \ 6 months was 3.482 (95% CI, 1.641–
7.388), compared to TFI C 6 months, showing statistical signiﬁcance
(P = 0.0012)
HR hazard ratio, TFI treatment-free interval
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123chemotherapy, received a variety of second-line chemo-
therapy against relapsed or recurrent tumors. The overall
response rate to second-line chemotherapy was 25% (0–
38%). The PFS was 3.5 months (0–20 months), and the OS
was 10 months (2–44 months). The response rates, PFS
and OS did not differ signiﬁcantly by the regimen of sec-
ond-line chemotherapy. Therefore, other factors associated
with the response to second-line chemotherapy were
investigated.
In the related ﬁeld of ovarian carcinomas, a TFI has
consistently been shown to be the most important factor in
the prediction of the response to the second-line chemo-
therapy [21–24]. Patients with ovarian tumor who relapse
within 6 months have a disease that is signiﬁcantly more
likely to be both resistant to the original drugs and to have
a lower response rate to new chemotherapy; however, those
who relapse after 6 months from a ﬁrst-line platinum-based
chemotherapy have a higher chance of responding well,
either to a re-challenge with a platinum-based treatment or
to other agents [21].
However, comparable predictive factors for the response
to second-line chemotherapy have not been established for
endometrial carcinomas. It was yet to be determined
whether TFI predicts a response to second-line chemo-
therapy, and if so, whether 6 months was a reasonable
critical threshold that would suggest the clinical outcome
after second-line chemotherapy. It was also unclear which
current regimen is most effective as a second-line chemo-
therapy for endometrial carcinoma.
In our study, a TFI greater or less than 6 months was
demonstrated to be signiﬁcantly associated with the
tumor’s likely responsiveness to a second-line chemother-
apy (P = 0.0026 by Fisher’s exact test). The current study
also showed that the association between TFI and sensi-
tivity to a second-line TECm, TCm or TCw was statisti-
cally signiﬁcant (P = 0.015 by Fisher’s exact test),
indicating that second-line chemotherapy using taxane and
platinum, with or without anthracycline, was not effective
for those whose TFI was shorter than 6 months after initial
treatment using taxane and platinum, with or without
anthracycline.
PFS and OS were also shown to relate to a TFI C or
\6 months (P = 0.0003 and P = 0.025, respectively, by
the log-rank test). As in ovarian tumors, multivariate
analysis showed that the TFI for endometrial tumors was
also the most signiﬁcant factor for predicting the effec-
tiveness of a second-line chemotherapy (the adjusted HR of
TFI (C6 months versus\6 months) on PFS: 3.482 (95%
CI, 1.641–7.388), and that on OS: 2.341 (95% CI, 1.034–
5.301)). TFI was demonstrated to be a signiﬁcant factor in
predicting for PFS and OS (P = 0.0012 and P = 0.042,
respectively, based on the multivariate Cox proportional
hazards model).
These results imply, for the ﬁrst time, that the standard
strategy for ovarian carcinoma second-line chemotherapy
can now be applied to endometrial carcinoma as well.
Endometrial carcinomas that relapse at least 6 months
after ﬁrst-line chemotherapy using TC/TEC have a sig-
niﬁcantly higher chance of responding to second-line
chemotherapy. However, the tumors that relapse before
6 months are likely to be resistant. In fact, none of the
currently popular regimens of chemotherapy (including
the same as, or other than, the ﬁrst-line regimen) were
effective, and the PFS and OS were only 2 months (0–
9 months) and 5.5 months (2–44 months), respectively
(data not shown). Palliative care in these cases, rather
than second-line chemotherapy, may for now be more
appropriate.
Our present study provides, for the ﬁrst time, good
evidence that relapsed or recurrent diseases found within
6 months from a ﬁrst-line chemotherapy regimen using
taxane and platinum (with or without anthracycline) fail to
respond to second-line chemotherapy. Further investigation
is still required to establish an efﬁcacious strategy for
second-line chemotherapy for advanced or recurrent
endometrial cancer.
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Table 6 Multivariate Cox proportional hazards analysis for effec-
tiveness of second-line chemotherapy on OS
Variable Adjusted HR 95% CI P value
Age (years) 0.081
\60 1
C60 0.497 0.228–1.085
Histology 0.40
Endometrioid 1
Non-endometrioid 1.497 0.590–3.800
Initial stage 0.30
I/II 1
III/IV 1.613 0.658–3.953
TFI 0.042
C6 months 1
\6 months 2.341 1.034–5.301
The adjusted HR of TFI \ 6 months was 2.341 (95% CI, 1.034–
5.301), compared to TFI C 6 months, showing statistical signiﬁcance
(P = 0.042)
HR hazard ratio, TFI treatment-free interval
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